Leiner pleads guilty
This article was originally published in The Tan Sheet
Executive Summary
Leiner Health Products formally pleads guilty to knowingly shipping 1,275 drug batches that failed stability tests, and will pay a $10 million fine to resolve allegations its Fort Mill, S.C., plant violated good manufacturing practices, according to court documents filed earlier this month. In exchange, the Department of Justice will not prosecute Leiner. The deal will not impact NBTY's plans to acquire the company for $371 million, NBTY CEO Harvey Kamil said (1"The Tan Sheet" June 16, 2008, p. 3)...
You may also be interested in...
NBTY Leiner Buy Intensifies Supplement Ingredient Competition
The dietary supplement ingredient supply market is set to become more competitive with NBTY's planned acquisition of Leiner Health Products
Part D Price Negotiation Round One: Several Likely Candidates May Not Feel The Cut
Heavily rebated drugs may already be meeting the price goals established by the Senate legislation. As a result, price negotiation for drugs covered under Part B are likely to yield greater savings to the Medicare program than Part D.
Senate Proposes Smaller Boost Than House For FDA FY2023 Appropriation
Senate Appropriations Committee proposes $1.185bn to CFSAN and $2.19bn to CDER, both levels short of House appropriators passed in June. FDA requested $30.36m in user fees from monograph drugs but no amount was specified in Senate draft bill.